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Abstract
Objective: Immunotherapy and gene therapy play important roles in modern medicine. 
The aim of this study is to evaluate the overexpression of interleukin-4 (IL-4), IL-10 and 
leukemia inhibitory factor (LIF) in Wharton’s jelly stem cells (WJSCs) in the experimental 
autoimmune encephalomyelitis (EAE) mice model. 
Materials and Methods: In this experimental study, a DNA construction containing IL-
4, IL-10 and LIF was assembled to make a polycistronic vector (as the transfer vector). 
Transfer and control vectors were co-transfected into Human Embryonic Kidney 293 
(HEK-293T) cells with helper plasmids which produced recombinant lentiviral viruses 
(rLV). WJSCs were transduced with rLV to make recombinant WJSC (rWJSC). In vitro 
protein and mRNA overexpression of IL-4, LIF, and IL-10 were evaluated using quanti-
tative polymerase chain reaction (qPCR), enzyme-linked immunosorbent assay (ELISA) 
and western blot (WB) analysis. EAE was induced in mice by MOG-CFA and pertussis 
toxin. EAE mice were injected twice with 2×105 rWJSCs. The in vivo level of IL-4, LIF, IL-10 
cytokines and IL-17 were measured by ELISA. Brain tissues were analyzed histologically 
for evaluation of EAE lesions.
Results: Isolated WJSCs were performed to characterize by in vitro differentiation and surface 
markers were analyzed by flow cytometry method. Cloning of a single lentiviral vector with 
five genes was done successfully. Transfection of transfer and control vectors were processed 
based on CaPO4 method with >90% efficiency. Recombinant viruses were produced and re-
sults of titration showed 2-3×107 infection-unit/ml. WJSCs were transduced using recombinant 
viruses. IL-4, IL-10 and LIF overexpression were confirmed by ELISA, WB and qPCR. The EAE 
mice treated with rWJSC showed reduction of Il-17, and brain lesions as well as brain cellular 
infiltration, in vivo. Weights and physical activity were improved in gene-treated group.                 
Conclusion: These results showed that gene therapy using anti-inflammatory cytokines 
can be a promising approach against multiple sclerosis (MS). In addition, considering the 
immunomodulatory potential of WJSCs, an approach using a combination of WJSCs and 
gene therapy will enhance the treatment efficacy.         
Keywords: Gene Therapy, Multiple Sclerosis, Wharton’s Jelly Stem Cells, Cytokines
Cell Journal(Yakhteh), Vol 19, No 3, Oct-Dec (Autumn) 2017, Pages: 361-374 
Citation: Hosseini A, Estiri H, Akhavan Niaki H, Alizadeh A,  Abdolhossein Zadeh B, Ghaderian SMH, Farjadfar A, Fallah A. 
Multiple sclerosis gene therapy using recombinant viral vectors: overexpression of IL-4, IL-10 and leukemia inhibitory factor 
in wharton’s jelly stem cells in the EAE mice model. Cell J. 2017; 19(3): 361-374. doi: 10.22074/cellj.2017.4497.
CELL JOURNAL(Yakhteh), Vol 19, No 3, Oct-Dec (Autumn) 2017 362
Hosseini et al.
Introduction
Autoimmune disease (AD) is defined as a 
malfunction of human immune system in which 
reactive immune system cells attack functional 
cells that will be destroyed following apoptosis 
(1). When the number of these dead cells reaches 
a critical number in a specific tissue, physiological 
functions will be disrupted and pathological 
symptoms of an AD will appear. Many tissues 
can be targeted by reactive immune cells (2). So 
far, over 150 ADs have been identified. Moreover, 
chronic inflammation is the initiating step in many 
diseases. Some of the most important ADs are 
multiple sclerosis (MS), type 1 diabetes (T1D), 
psoriasis, rheumatoid arthritis (RA), systemic 
lupus erythematosus (SLE), autoimmune thyroid 
diseases and inflammatory bowel diseases. Many 
specialists agree that chronic inflammation 
leads to ADs (3). Considering the inflammation, 
cytokines are divided into pro-inflammatory and 
anti-inflammatory cytokines. Cytokines such 
as interleukin-4 (IL-4), IL-10, IL-13, leukemia 
inhibitory factor (LIF), transforming growth factor-
beta (TGF-β) and FasL are anti-inflammatory 
cytokines.
MS is the most common chronic inflammatory 
disease in which demyelination occurs in the 
central nervous system, leading to neurological 
disabilities. The most common class of MS is 
relapsing-remitting MS (RRMS) which is present 
in more than 80 percent of the patients. MS 
typically starts at the age of 20-30 years, with a 
female predominance that recently has reached a 
ratio of 3:1 in comparison to males. Nowadays, 
there is no treatment to stop the progression of 
MS or to reverse its neuropathology (4). Anti-
inflammatory molecules can be considered as the 
forefront of MS and other autoimmune diseases. 
New advanced technologies like gene therapy 
and immunotherapy, are able to introduce new 
treatments against MS. Monoclonal antibodies as 
an effective and targeted immunotherapy, play an 
important role in modern medicine. Natalizumab, 
alemtuzumab, rituximab, ofatumumab, and 
secukinumab are monoclonal antibodies approved 
for MS treatment. Most of these monoclonal 
antibodies like secukinumab, inhibit IL-17 or 
other pro-inflammatory proteins that play a major 
role in MS initiation and progression (5).
Moreover, anti-inflammatory gene therapy 
is another approach against MS. There have 
been many controversial arguments on the pro-
inflammatory and anti-inflammatory functions of 
human cytokines. In the literature, IL-4, LIF, IL-10 
are mentioned as anti-inflammatory cytokines while 
IL-17 has been accepted as a pro-inflammatory 
cytokine. Inhibition of pro-inflammatory cytokines 
and overexpression of anti-inflammatory cytokines 
can be effective approaches in the gene therapy of 
ADs (6). IL-4 is a key effector in the differentiation 
of CD4+ cells into type 2 helper (TH2) cells. IL-4 
works as an anti-inflammatory cytokine, TH1 cell 
suppressor, and intracellular pathogen protector. 
Tissue macrophages produce IL-4, that in turn 
suppresses tumor necrosis factor-alpha (TNF-α) 
and IL-1β. In inflamed tissue, massive production 
of IL-4, IL-10, and other anti-inflammatory factors 
such as LIF and IL-27, make TH2 the predominant 
subtype of T cell. In inflamed tissues, IL-4 activates 
lipopolysaccharide (LPS) and suppressor of 
cytokine signalling-1 (SOCS1) as the downstream 
effectors (7). It has been shown that injection of 
recombinant adeno-associated virus (AAV) and 
naked plasmids coding IL-4 can treat AD in the 
animal models (8).
IL-10 is a potent anti-inflammatory cytokine 
produced by monocytes and lymphocytes. IL-
10 suppresses the expression of many common 
inflammatory cytokines. Furthermore, IL-10 
knockout animals are susceptible to human 
immunodeficiency virus 1 (HIV-1) infection 
and rheumatoid arthritis disease (9). IL-10 
administration as a naked plasmid, liposomal 
particle, recombinant adenovirus, naked plasmid 
and transduced cells, shows therapeutic effects 
on autoimmune diseases (8). LIF cytokine 
has protective properties for neuron and 
oligodendrocyte that makes it a therapeutic 
candidate for MS. LIF is a pro-inflammatory 
cytokine with strong immunomodulatory effects 
as it inhibits TH17 differentiation which enhances 
neuron myelination by oligodendrocytes. LIF 
downregulates the autoimmune response by 
enhancing Treg cell numbers, making it a novel 
promising treatment for MS and other autoimmune 
diseases (10).
Human Wharton’s jelly stem cells (WJSCs) are 
assembled in large scale from neonatal tissues. 
WJSCs are pluripotent stem cells with the 
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potential of differentiation into mesodermal, 
ectodermal, and endodermal lineages (11). 
These cells possess immunosuppressive 
activities with minimum stimulation of immune 
and inflammatory systems, suggesting them 
as a good cell resource for cell therapy and 
regenerative medicine. The umbilical cord is a 
more accessible and minimally invasive source 
of WJSCs. Umbilical cord WJSCs have a higher 
proliferation rate in comparison to adult and 
fetal stem cells (12). However, most of the 
procedures used for ex vivo WJSCs isolation, 
expansion and differentiation are based on 
animal or human serum-containing medium, 
representing a major limitation for clinical 
applications.
Immunotherapy and gene therapy play 
important roles in modern medicine. Here, three 
anti-inflammatory genes (IL-4, LIF, and IL-
10) were combined in a single lentiviral vector. 
Overexpression of these genes in WJSCs, which 
has immunomodulatory properties, might result in 
an effective co-application of cell and gene therapy 
for the treatment of the experimental autoimmune 
encephalomyelitis (EAE) mice model.
Materials and Methods
Polycistronic lentiviral vector construction
In this experimental study, premade dual-
promoter lentivector, pCDH-513B was purchased 
(SystemBio, USA) as a backbone vector. The 
pCDH-513B contains two promoters namely, 
cytomegalovirus (CMV) and phosphorus glycerol 
kinase (PGK). After CMV, multiple cloning site 
(MCS) is used for gene cloning. PGK promoter 
mediates the co-expression of CopA-GFP (cGFP) 
and puromycin as single mRNA. Cloning of 
Thosea asigna virus 2A (T2A) self-cleavage 
peptide between these two proteins sequence 
leads to separate release of the proteins from 
the ribosome. The vector is a third generation 
lentiviral vector with the chimeric Rous sarcoma 
virus-long terminal repeat (RSV-5ˊLTR) promoter 
that leads to Tat-independent, 5ˊLTR-GOI-3ˊLTR 
RNAs transcription in packaging process.
According to the manufacturer’s protocol, 
tricistronic human genes of IL-4, LIF, IL-10 
were constructed using Gibson Assembly kit 
(NEB,USA ). Briefly, genes cDNA were purchased 
(GE Healthcare,USA) and primers were designed 
with 20 bp overlaps for genes and vector by using 
online NEBuilder software. Primers were used 
for amplified genes by using proofreading DNA 
polymerase, Pfu (Thermofisher, USA). Two P2A 
self-cleavage peptides were assembled between 
the genes open reading frames (ORF) to guarantee 
the monomeric protein release from the ribosome 
in the translation process. In a single tube, all five 
DNA fragments were cloned in pCDH-513B, 
and linearlized with BstBI restriction enzyme 
(NEB, USA). A few right clones were purified 
using miniprep plasmid kit (Thermofisher, USA) 
after transformation and colony PCR. Following 
confirmation of a few clones by digestion, two 
correctly digested clones were sent for sequencing. 
Correct sequence of transfer vector (pCHD-CMV-
ILI-EF-GP), that contained IL-4, LIF, IL-10, 
GFP and puromycin genes were confirmed by the 
sequencing. Empty vector which only contained 
GFP and puromycin, was used as the control 
vector.
Human Wharton’s jelly stem cell isolation, 
expansion, and characterization
Human healthy umbilical cord were obtained 
from hospitalized children after obtaining the 
bioethics commission’s approval and paternal 
agreements. Umbilical cord was washed three 
times with phosphate-buffered saline (PBS) for 
removing blood cells and coagulations. Umbili-
cal cord amnion membrane was removed and 
exposed to jelly tissue. After cutting umbilical 
cord vertically with 2.5 mm surgical punch, one 
vein, and two arteries were physically removed. 
About 10-20 umbilical cord pieces were isolated 
and washed with PBS contained penicillin (200 
U/ml) streptomycin (200 µg/ml, Gibco, USA) 
and amphotericin B (3 µg/mL, Gibco, USA). 
Umbilical cord pieces were cultured in a six-
well plate with a minimum of Dulbecco’s Mod-
ified Eagle Medium containing Nutrient Mix-
ture F-12 (DMEM/F12) medium (Gibco, USA), 
supplemented with  30-40% fetal bovine serum 
(FBS, Gibco, USA). Umbilical cord pieces cul-
tured in six-well plates were incubated at 37°C 
with 5% CO2. The same amount of the medium 
was added in the next 24 and 72 hours to em-
bedded pieces. In the first days of culture, it is 
critical that tissue sections adhere to plate sur-
face to allow cell migration and deviation. After 
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one week, solid umbilical cord pieces were re-
moved and cell migration was evaluated under 
the invert light microscope. The tissues were 
removed after one week and supplemented with 
fresh medium until cells reached >70-80% con-
fluence. Cells were passaged until they reached 
the confluency of 80%.
For adipose differentiation 1×105 WJSCs 
were cultured in six-well plates. After reaching 
a 40-50% confluency, an adipogenic differen-
tiation medium (Gibco, USA) was added to the 
basic medium. Fresh adipogenic medium was 
replaced every 72 hours for 20-25 days. After 
about 20 days, cells were fixed with paraform-
aldehyde, and washed with sterile water and 
60% isopropanol. Then, lipid droplets were vis-
ualized using Oil Red O (Sigma-Aldrich, USA) 
staining. In the control group, WJSCs cells 
were grown in culture medium without adipo-
genic differentiation medium.
For osteogenic differentiation, a six-well plate 
was cultured with 1×105 cells per well. After 
reaching a 40-45% cell confluency, osteogenesis 
supplement (Gibco, USA) was added to the basic 
medium. Fresh osteogenic medium was replaced 
every 72 hours for 20-25 days. After about 20 
days, cells were fixed and evaluated using Alizarin 
Red (Sigma-Aldrich, USA). Alizarin red stains the 
calcium deposits confirming osteogenic differen-
tiation. In the control group, WJSCs were grown 
in the culture medium without osteogenesis sup-
plements.
Flow cytometry analysis
WJSCs are positive for specific stem cell 
markers such as CD44, CD73, CD90 and CD105 
but negative for CD34 and CD45 hematopoietic 
markers. A small fraction of undifferentiated 
WJSCs,  (passage 3, 105 cells) were analyzed 
using BD FACSCalibur flow cytometry (BD 
Bioscience, USA) for the expression of WJSCs 
surface markers by using specific antibodies 
at the recommended concentrations. After 
addition of antibodies, tubes were incubated 
in the dark at the room temperature for 30-60 
minutes. Next, flow cytometry analysis was 
performed and then data was analyzed using 
FlowJo (version 7.6.1) software.
Recombinant lentivirus production, concentration, 
and titration
The transfer vector (pCHD-CMV-ILI-EF-GP) 
and control vector (pCDH-EF-GP) were used for 
packaging. For the production of recombinant 
lentivirus (rLV), a 3rd generation system was 
used. CaPO4 protocol was used according to 
Trono Lab with some modifications. Transfer/
control vector 21 µg , pMD2.G vector 7.5 µg, 
pMDLg/pRRE vector 15 µg and pRSV-Rev 
vector 13 µg were dissolved in HEPES buffered 
water to reach 921 µl. Then, 33 µl Tris-EDTA 
(TE) buffer was added and the mixture was 
strongly mixed and left for 3 minutes at room 
temperature (RT). Next, 105 µl CaCl2 2.5 M was 
added and the mixture was strongly vortexed. 
The mixture was left for 3 min for making DNA-
CaCl2 interaction; then, 1074 µl HEPES 2X was 
added while the mixture was being vortexed. 
Finally, 2100 µl master mix was used per 10 
cm HEK-293T cells with 70% confluency. 
Transfection master mix was added as a droplet 
to all area of the plate. HEK-293T cells medium 
was changed 2 hours before transfection using 
10 ml fresh medium containing 10% FBS.
Transfection medium was replaced with 13 
ml fresh medium containing 10% FBS, 14-17 
hours post-transfection. After 24 hours, the rate 
of transfections was determined by counting 
GFP positive and negative cells under florescent 
microscope. Supernatant was collected after 24, 
48 and 72 hours. Pooled recombinant viruses were 
passed through 0.24 µm pore filters. Recombinant 
lentiviral concentration was measured based on 
polyethylene glycol (PEG) method. PEG 600 
50%, NaCl4 M, and PBS were added to pooled 
recombinant viruses inside polypropylene bottles. 
Bottles were mixed every 30 minutes and stored at 
4°C for 1.5 hours. Then, tubes were centrifuged at 
7000 g for 15 minutes at 4°C. According to Trono 
Lab protocols, recombinant lentiviral titration was 
proceeded with WPRE primers:
F: 5ˊACTGTGTTTGCTGACGCAAC3ˊ 
R: 5ˊCAACACCACGGAATTGTCAG3ˊ and 
quantitative polymerase chain reaction (PCR) (13).
Fresh viruses at volumes of 1000, 500, 100, 50, 
20 and 0 μl were used for transducing HCT119 
cells in a 12-well plate. Concentrated viruses at 
volumes of 4, 2, 1, 10-1, 10-2 and 0 μl were used 
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for transducing HCT119 cells in a 12-well plate. 
Naked transfer vector was used for plotting the 
standard curve. Recombinant titrated virus were 
stored at -70°C (with less than three times of 
freeze-thaw) for future use. 
WJSCs transduction and MTT cell proliferation 
assay
WJSCs were cultured at a low confluency of 
30-40% in a six-well plate. Recombinant viruses 
from transfer vector and control vector were 
used in multiple of infections (MOI) 5-10 for 
transduction. Cell transduction was evaluated 
using fluorescent microscope, 72 hours after the 
transduction. Puromycin (1.5 µg/ml) selection 
started 72 hours after transduction, for the 
next 5 days. For MTT assay, 8×103 cells were 
cultured from transduced WJCSs and normal 
WJCSs in 96-wells plates, 24 hours before 
the assessment. After 24 hours, MTT reagents 
were added and incubated for 4 hours. Reaction 
was terminated with the addition of dimethyl 
sulfoxide (DMSO) and the plate was read at 
570 nm wavelength using BioTek Instruments 
(Vermont, United States) microplate reader.
Quantitative polymerase chain reaction 
Total RNA was extracted extracted from 
transduced cells using the mRNA extraction kit 
(Qiagen, Germany) according to manufacturer’s 
protocol. Real-time PCR was carried out using 
0.5 μg RNA with SYBR Green. Primers used for 
qPCR are listed in Table 1. Data was presented 
as the ratio of mean threshold targeted human 
exogenous genes expression to human endogenous 
GAPDH. For each gene, the specificity of the PCR 
product was assessed by verifying a single peak on 
the plots obtained from the melting curve analysis.
Western blot analysis
Recombinant WJSCs supernatants were collected 
72 hours after transduction. Protein concentrations 
in the supernatants were determined using a BCA 
Protein Assay Kit (Thermo Fisher, USA). Then, 
protein (30 µg/lane) was loaded onto 12% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) with protein marker and transferred 
onto nitrocellulose membranes (Bio-Rad, USA). 
The membranes were blocked using 5% non-fat 
milk and immunoblotting was performed using 
antibodies against IL-4 (Santa Cruz, USA), LIF 
(Abcam, UK), IL-10 (Santa Cruz, USA) and 
β-actin (Abcam, UK). Proteins of interest were 
detected using HRP-conjugated sheep anti-mouse 
IgG antibody (Abcam, ab6785). Finally, the protein 
band was visualized by chemiluminescence reagent 
(ECL) and the integrated optical density (IOD) of 
each protein band was measured. IOD values were 
adjusted against the internal standard, β-actin.
Table 1: Human primers used for quantitative PCR for determination of overexpression
Primer name Primer sequence (5ˊ-3ˊ) Product size (bp) Tm 
IL-4 F: ACTGCACAGCAGTTCCACAG 115 60.10
R: CTCTGGTTGGCTTCCTTCAC 59.84
LIF F: GTTCCCCAACAACCTGGAC 165 60.21
R: GGGGTTGAGGATCTTCTGGT 60.31
IL-10 F: TTACCTGGAGGAGGTGATGC 147 60.07
R: GGCCTTGCTCTTGTTTTCAC 59.86
GAPDH F:  CGAGATCCCTCCAAAATCAA 293 60.01
 R:  TGTGGTCATGAGTCCTTCCA 60.09
PCR; Polymerase chain reaction and Tm; Melting temperature. 
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Experimental autoimmune encephalomyelitis 
induction and treatment
Female C57BL/6 mice, 7-9 weeks old, were 
used in this study. EAE was induced according 
to the standard protocol using MOG35-55 
(Sigma-Aldrich, USA) suspended in CFA 
(Sigma-Aldrich, USA). MOG-CFA emulsion 
was prepared by adding 200 µg MOG to 100 
µl PBS and 100 µl CFA per mouse. MOG-CFA 
was made for 20 mice after mixing 4 mg MOG 
with 2 ml PBS and 2 ml CFA. Then, MOG-CFA 
was vortexed for at least 45 minutes within 
7-ml Borosilicate glass (Fisher Scientific, 
USA). After 30 minutes the emulsion was 
stable. Then, 200 µl MOG-CFA per mouse was 
injected in two dorsal regions of hind limbs and 
forelimbs. Afterwards, 400 ng of pertussis toxin 
(PTX, Sigma-Aldrich, USA) was diluted in 200 
µl PBS. PTX was intraperitoneally injected for 
two times: once immediately after the MOG-
CFA injection and the other, 48 hours after 
the MOG-CFA injection. Weights and clinical 
scores were evaluated daily.
Therapeutic effect of IL-4, LIF, and IL-10 
administration was evaluated in three groups of 
mice with EAE that had been randomly divided. 
The first group of EAE mice received WJSCs 
without genetic engineering, the second group 
of them received WJSCs transduced with control 
vector and the third group of EAE mice received 
WJSCs that was transduced with transfer vectors 
carrying IL-4, LIF, and IL-10 genes. In all groups, 
cells were collected following trypsinization. 
Then the cells were suspended and counted before 
the injection. Each mouse received 2×105 cells 
through the tail vein two times on days 15 and 20 
after EAE induction.
In vitro and plasma assay of cytokines level
 Two months after immunization and 40-45 days 
after injection of transduced cells, spleen cells 
were collected, cell suspensions were prepared in 
96-well plates, and 50 ng/ml antigen (MOG35-
55 peptide) was added to RPMI medium. After 
72 hours of culture, supernatants were collected 
and analyzed for cytokines using mouse IL-17 
ELISA kit (Abcam, UK). Also, for investigation 
of the level of overexpression, supernatants 
from transduced rWJSCs were evaluated using 
enzyme-linked immunosorbent assay (ELISA). 
After 72 hours of culturing of transduced rWJSCs, 
supernatants were collected and analyzed for 
cytokines production using IL-4, IL-10 and LIF 
ELISA Kits (Abcam, UK). Fifty five days post-
immunization, blood samples were collected from 
the mice to analyze circulating levels of IL-4, IL-
10, LIF and IL-17 by ELISA assay according to 
the manufacturer’s protocol (Abcam, UK). The 
concentration of each cytokine was calculated 
based on the plotted standard curve.
Tissue processing and histological analysis
Thirty days post-transplantation, the animals 
were sacrificed. Brain tissues were harvested and 
fixed in 10% formalin. Fixed tissue was cut in 
6-µm sections and stained with hematoxylin and 
eosin (H&E). Then, brain cellular infiltration, as a 
physiopathology marker, was evaluated.
Weight and clinical scoring
EAE mice were checked for weight loss every 24 
hours. Mice were daily monitored for clinical signs 
of EAE. Typically, EAE is scored on a scale from 0 
to 5: A score of 0 shows no obvious changes in motor 
function in comparison with non-immunized mice; A 
score of 1 means limp tail; A score of 2 means limp tail 
and weakness of hind legs; A score of 3 means limp 
tail and complete paralysis of hind legs or limp tail 
with paralysis of one front and one hind leg; A score 
of 4 means limp tail, complete hind leg, and partial 
front leg paralysis and  A score of 5 demonstrates 
spontaneously rolling in the cage.
Results
Construction of polycistronic lentiviral vector
Polycistronic vector containing IL-4, LIF and IL-
10 was constructed using DNA assembling method 
(14). Sequences of all three genes were confirmed 
following enzymatic digestion and sequencing. 
Cloned two P2A self-cleavage peptide sequence 
after IL-4 and LIF confirmed the release of all three 
genes which was independent from the ribosome 
with self-cleavage after glycine and before prolin 
in P2A protein sequence. In this construct, IL-4, 
LIF, and IL-10 mRNA were transcript from CMV 
promoter and cGFP and Puromycin mRNA were 
transcript from EF promoter. Transfer vector 
expressed five proteins from two transcript 
mRNAs as shown in Figure 1.
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Fig.1: Polycistronic third generation lentiviral vector. Cloning of RSV promoter before 5ˊ-LTR makes Tat-independent and third 
generation lentiviral vector. RSV makes whole viral genome transcription in packaging process. Two transcriptions derived 
from CMV and EF1 promoters. Introducing P2A and T2A self-cleavage peptides secures grantee releasing each proteins 
meanwhile of translation of mRNA in ribosome. This polycistronic lentiviral overexpression five protein simultaneously in 
transducted cells.  
RSV; Rous sarcoma virus, LTR; Long terminal repeat, CMV; Cytomegalovirus, EF1; Elongation factor-1, P2A; Porcine teschovirus-1 2A, and 
T2A; Thoseaasigna virus 2A.
Extraction, characterization, and differentiation 
of WJSCs
The WJSCs were collected from the umbilical 
cords (n=2) retrieved from healthy full-term 
women with elective cesarean delivery. Cells 
were isolated without any enzymatic digestion, 
only based on cell migration and surface 
attachment. The vein and artery were removed 
from umbilical cord sections. Following tissues 
adhesion and cells migration, fibroblastic-like 
morphology of the cells were confirmed under 
invert microscope. Cells were expanded through 
more than 10 passages with no significant 
differences among cultures. The success of 
obtaining human WJSCs without any enzymatic 
interventions was previously reported (15). 
Immunophenotyping of cell-surface antigens 
were done in the third passage and the identity 
and properties of WJSCs were confirmed by 
flow cytometry analysis. WJSCs were positive 
for CD44, CD105, CD90, and CD73 markers 
and negative for hematopoietic markers, CD45, 
and CD34 (Fig.2). Also, the capacity of WJSCs 
in differentiating into adipogenic and osteogenic 
cells, was evaluated. The accumulation of lipid 
vacuoles were demonstrated by Oil Red O 
staining (Figs.3A, B) and calcium deposition 
was revealed by Alizarin Red (Fig.3C).
Recombinant lentiviral production, concentra-
tion, titration and transduction
Transfer and control vector were transfected 
in HEK-293T cells using CaPO4 method. Based 
on GFP positive and negative cells counted 
under fluorescent microscope, transfection rate 
was higher than 90% (Fig.4A, B). Recombinant 
virus titrations were done using quantitative 
PCR (qPCR), and based on our data, fresh 
viruses titration was 1-2.3×106 particles/ml. 
Concentrated viruses titration raised to 2-3×107 
infection-unit/ml. Recombinant lentiviral 
concentration was evaluated using PEG 6000 
and the mixture was centrifuged at 7000 g. 
Results showed that short-term centrifugation 
of recombinant viruses results in at least 10 
times more recombinant viruses. Concentration 
causes the loss of about 15-20% of initiation 
recombinant viruses. Cells transduced with 
fresh viruses without concentration and 
selection with puromycin demonstrated the 
desired result. Transduction of WJSCs with 
concentrated and fresh recombinant viruses 
(MOI 5-10) does not show any significant 
difference (Fig.4C). Puromycin (1.5 µg/ml) was 
used for the selection of transduced WJSCs.
MS Gene Therapy IL-4, LIF, IL-10
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Fig.2: Immunotyping of Wharton’s jelly stem cells (WJSCs). Flow cytometry analysis of WJSCs populations showed positive marker for A. 
CD44 (98.60%), B. CD105 (91.40 %), C. CD90 (98.30 %), D. CD73 (95.90%) and negative marker for E. CD45 (4.75 %), and F. CD34 (2.74%). 
Results showed that more than 95% of WJSCs are positive for mesenchymal stem cell markers and negative for hematopoietic stem cells 
markers.
A B
C D
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Fig.3: Isolation and diffraction of Wharton’s jelly stem cells 
(WJSCs) from umbilical cords. A. The isolated WJSCs were 
cultured in DMEM-F12 and showed fibroblasts morphology, 
B. As was showed in, oil droplets confirmed adipogenic 
differentiation, and C. Stained mineral calcium indicated 
osteogenic differentiation.
Fig.4: Transfection of lentiviral transfer vector in HEK-293T and 
transduction of Wharton’s jelly stem cells (WJSCs) were assessed 
with expression of copaGFP under fluorescent microscope. A. 
Transfected cells under fluorescent microscope were showed, B. 
Cells were illustrated simultaneously in open light and fluorescent 
microscope image. Comparing both pictures shows the high 
transfection efficiency is higher than 90%, and C. Transduction 
of WJSCs were verified with expression of copaGFP.
A
B
C
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Cell viability
MTT assay showed that transduction and 
overexpression of genes do not have significant 
effect on the viability of transcduced cells in 
comparison with non-transduced cells (P>0.05). 
These results showed that transduction and 
genome integration of transfer lentiviral vector did 
not have any effect on WJSCs viability. Viability 
in different MOI had no significant differences 
(P>0.05) as compared with normal WJSCs (Fig.5). 
Fig.5: Transducted Wharton’s jelly stem cells (WJSCs) with transfer 
vector were assayed for viability with MTT test. As showed in 
picture, cell growth, and viability are the same in transducted 
WJSCs and normal WJSC cells (P>0.05). Transducted WJSCs viability 
in different MOIs have no significant versions (P>0.05).
In vitro and in vivo gene overexpression assay
In vitro expression of IL-4, LIF and IL-10 were 
confirmed using qPCR and ELISA. QPCR was per-
formed for human IL-4, LIF, and IL-10 exogenous 
genes against GAPDH endogenous gene as control. 
As shown in Figure 6, exogenous genes were sig-
nificantly overexpressed in WJSCs transduced with 
transfer vector in comparison to WJSCs transduced 
with control vector (P<0.05). For measurement of IL-
4, IL-10 and LIF production by transduced MSCs, an 
ELISA sandwich was done using supernatants, after 
72 hours of culture. The results indicated that IL-4, 
IL-10 and LIF produced by WJSCs transducted with 
transfer vector were significantly higher than those of 
controls (P<0.05).
Exogenous human genes of IL-4, LIF, IL-10 and 
endogenous mouse IL-17 were measured using ELI-
SA standard test on plasma obtained from mice that 
received WJSCs or WJSCs transduced with transfer 
or WJSCs transduced with control vectors. Bloods 
were collected from mice tail vein. As shown in Fig-
ure 7, expression of anti-inflammatory exogenous 
genes was significantly increased (P<0.05) and IL-17 
pro-inflammatory gene was decreased in treatment 
group (P<0.05). The Results of IL-17 ELISA in un-
treated EAE mice, EAE mice treated with WJSCs, 
EAE mice treated with WJSCs transduced with con-
trol vector and EAE mice treated with WJSCs trans-
duced with transfer vector, indicated that WJSCs has 
baseline anti-inflammatory properties. Transfer vec-
tor with IL-4, IL-10 and LIF decreased IL-17 level in 
EAE mice blood.
Fig.6: QPCR analysis of transducted Wharton’s jelly stem cells 
(WJSCs). All three genes (IL-4, IL-10 and LIF) encoded with transfer 
vector showed significant overexpression in compare with 
endogens GPDH gene (P<0.05).
QPCR; Quantity polymerase chain reaction and LIF; Leukemia 
inhibitory factor.
Western blot results confirmed gene expression data 
at the protein level. All three proteins are expressed by 
transfer vector (Fig.8). Western blot analysis showed 
similar expression levels for β-actin protein in both 
control and transduced WJSCs in comparison with 
IL-4, IL-10 and LIF proteins that were only overex-
pressed in transduced WJSCs (Fig.9).
These results confirmed the gene transfer and gene 
overexpression in WJSCs. qPCR showed the overex-
pression of the genes at the mRNA level. In addition, 
in vivo and in vitro ELISA tests confirmed proteins 
expression in geneticly engineered WJSCs. For more 
specific confirmation, overexpressed proteins were 
detected by western blot. These results showed that 
all proteins were transcribed and translated correctly.
The EAE mice model and therapeutic gene therapy
In our experiment, EAE induction was successful 
as measuring weights and physical activities of 
mice confirmed the induction of EAE in mice 
(with EAE scores of about 4-5, Fig.10). 
Ex vivo gene therapy of EAE mice with these cells 
showed reduction of MS pathology in a mice model. 
As shown in Figure 11A, in control group without 
EAE, normal brain tissue was observed. Untreated 
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EAE mice showed brain tissue with wide range of 
cellular infiltration (Figure 11B). Moreover, the result 
of injection of WJSCs transduced with control virus 
which only carried cGFP and puromycin are shown in 
Figure 11C. Immunomodulation and neuroprotection 
of IL-4, IL-10 and LIF gene therapy in treatment group 
were confirmed by reductions in IL-17 and brain cel-
lular infiltration (Fig.11D). Weight measurements and 
physical activity observation indicate EAE recovery 
after gene therapy. In EAE mice that only received 
WJSCs without gene therapy, the treatment efficacy 
was limited but detectable. On the other hand, in EAE 
mice receiving WJSCs transduced with transfer vec-
tor, physical activities and weights were improved. 
 
Fig.7: In vitro ELISA assay on transducted Wharton’s jelly stem cells 
(WJSCs) with control and transfer vectors compared here. As shown, 
there are increase in protein expression level, A. IL-4, B. IL-10, and 
C. LIF in transducted WJSCs with control and transfer vectors in 
compare to other groups. LIF; Leukemia inhibitory factor.
Fig.8: In vivo cytosines analysis. A. In vivo ELISA assay shows 
in the group that received Wharton’s jelly stem cells (WJSCs) 
transducted with transfer vector 55 days post experimental 
autoimmune encephalomyelitis (EAE) induction. As we see 
overexpressed genes have therapeutic level about 20 ng/ml in 
the blood but IL-17 decreased to about 5 ng/ml and B. IL-17 
as pro-inflammatory cytokine, indexed EAE induced mice that 
received different treatment or no treatment.
Fig.9: Western blot images here show from transfer vector 
and control vector after transduction Wharton’s jelly stem 
cells (WJSCs). As in first column was showed IL-4, IL-10 and LIF 
expressed from transfer vector. In right column, β-actin only 
detected as control. LIF; Leukemia inhibitory factor.
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Fig.11: Immunohistology analysis. H&E staining of brain in: A. Normal mice without brain lesions and cell infiltration foci, B. 
Experimental autoimmune encephalomyelitis (EAE) induced mice with no treatment Fcondensed cell infiltration foci and brain 
lesion are visible, C. EAE induced mice were treated with WJSCs again cell infiltration and brain lesions are visible but less that 
untreated group, and D. EAE induced mice treated with WJSC transducted with transfer vector shows more reduction of brain 
lesions and cell infiltration foci.
A B
Fig.10: Assessment of experimental autoimmune encephalomyelitis (EAE) induced mice with weight and physical activity 
measurement. A. Right mouse lost physical activity in compare with left once that can lift the body and B. Image shows scoring 
of EAE induction.
A B
C D
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Discussion
Autoimmune diseases are the outcome of 
chronic inflammation. Indeed, many types of 
autoimmune diseases are due to an imbalance of 
pro-inflammatory and anti-inflammatory cytokines 
(16). MS like other ADs has pathologic symptoms 
of the attacking of immune cells to myelin sheath 
of the central nervous system neurons (17). A 
few therapeutic approaches have been proposed 
for MS teratment. Currently, immunomodulatory 
and immunosuppressive approaches have reduced 
the number of relapses but none of them cure the 
existing deficits nor improve long-term disabilities 
in MS patients. Small molecules, recombinant 
proteins and recently, monoclonal antibodies are 
some of the available therapies for MS (18). Gene 
therapy and cell therapy combination could be 
considered as a powerful therapeutic solution for 
MS treatment in future.
In this study, three pro-inflammatory cytokine 
genes were constructed as a single lentiviral vector. 
This DNA was constructed using P2A self-cleavage 
peptide to guarantee the expression and release 
of IL-4, IL-10, and LIF. Studies have shown the 
therapeutic effect of these cytokines in autoimmune 
diseases (19). In this study, WJSCs were employed 
as an effective source of stem cells for cell therapy. 
Pluripotency of these cells was confirmed by flow 
cytometery and in vitro differentiation. In addition, 
transplantation of these cells showed modest effect 
on EAE pathology. In the present study, lentiviral 
was used as a transfer vector for gene therapy. 
Lentiviral vectors show high efficiency in target 
cell transduction. Titration of lentiviral vector 
was done and confirmed that high titers of these 
recombinant viruses were achieved. Integration of 
this recombinant virus guarantees the expression 
of these genes for a long time without reduction of 
expression as reflected by visualization of cGFP as 
an index. Random integration of this recombinant 
virus leads to oncogenicity with integration in pro-
oncogene genes. Despite this limitation, lentiviral 
vectors are the first choice for gene therapy and 
chimeric antigen receptors (CARs) T cell therapy 
in clinical trials (20, 21).
A previous study showed the beneficial effect of 
IL-4, IL-10 and LIF as autoimmune gene therapy 
agents (22). In this study, the combination of all 
these cytokines as a novel autoimmune gene 
therapy approach was investigated. The ultimate 
goal of autoimmune gene therapy is to restore and 
maintain the immune tolerance to the relevant 
autoantigens and improve the therapeutic effects 
of cytokines. In this study IL-4, IL-10 and LIF 
anti-inflammatory gene therapy was combined 
with immunomodulatory effects of human WJSCs 
as a novel ex vivo gene therapy for ADs. IL-
17 plays a central role in autoimmune disease. 
American food and drug administration (FDA) 
approved monoclonal antibodies against IL-17 
and its receptors, indicating the importance of 
suppression of this gene and its receptors ADs 
treatments (22). In this study, it was shown that 
lentiviral-mediated ex vivo overexpression of 
anti-inflammatory cytokines leads to reduction 
of IL-17, in vivo. Many of autoimmune therapies 
focus on reduction of IL-17 and Th17 functions. 
Here, we demonstrated an efficient method for 
reduction of IL-17 in an EAE mice model of MS. 
The therapeutic advantages of WJSCs and IL-4, 
LIF, and IL-10 anti-inflammatory cytokines may 
enable us to develop an effective approach to 
overcome MS.
This study showed the efficiency of gene ther-
apy in autoimmune diseases. Immunotherapy 
with recombinant monoclonal antibodies (mAbs) 
is expensive and most of the poor and undevel-
oped countries cannot afford recombinant mAbs 
as a regular therapy. Gene therapy approach for 
delivery of therapeutic mAbs or proinflammatory 
cytokines, can be considered as the next genera-
tion of immunotherapy. Introducing mAbs genes 
or therapeutic cytokines allows the patients’ own 
cells, to express these therapeutic agents without 
needing recombinant production, purification, and 
formulation In comparison with short half-life of 
recombinant proteins in the body, RNA and gene 
therapy show long lasting protein expression and 
they are considered as alternatives for recom-
binant proteins in immunotherapy. Ex vivo gene 
therapy with lentiviral vector could be a promising 
tool in modern medicine (23). In CAR T cell ther-
apy, as an emerging field of biotherapeutic agents, 
lentiviral vectors are dominant gene-transfer sys-
tems. Many pioneer gene-therapy companies, like 
Oxford Biomedica and Blubird Bio use lentiviral 
vectors as gene-transfer systems (24). In addi-
tion, combination of lentiviral vectors with novel 
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stem cell sources like WJSCs can make a brilliant 
perspective for the future of gene therapy usage 
against autoimmune diseases (25).
 
Conclusion
Synergistic expression of three cytokines (IL-
4, LIF, and IL-10) from a single promoter led 
to more marked anti-inflammatory effects as 
compared to single gene therapy approaches.  In 
this study, WJSCs which exert immunomodulatory 
properties, were used as carrier cells for gene 
therapy. Five genes were overexpressed in WJSCs 
with high efficiency. Altogether anti-inflammatory 
genes (IL-4, LIF, and IL-10), lentiviral vectors and 
WJSCs combination as and ex vivo gene therapy 
method, could be suggested as a novel gene 
therapy approach for ADs.
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